Biomoda (OTCBB: BMOD) released top line results for its pilot study for lung cancer and we are pleased with what we saw. In short, the study provides evidence to conclude that the Company’s biomarker assay, CyPath, can discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner.
The key to cancer survival, whether it is lung cancer or any other form of cancer, is early detection. And based on results from this study, Biomoda is able to identify and quantify cellular characteristics that differ between groups of individuals at high risk for developing cancer and those who already have the disease. At this point, this is exactly what the Company was hoping for. Going forward there are certain areas which can be improved, but that is really just tweaking that which we know works.
Congrats to the Biomoda team for a job well done. We look forward to continued success from the Company.